108138-46-1

Basic information

• Product Name: Tosufloxacin
• Synonyms: Tosufloxacin Tosyiate;7-(3-Amino-1-pyrrolidinyl)-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acid;dl-Tosufloxacin;TOSUFLOXACIN(SUBJECTTOPATENTFREE);7-(3-Aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;Tosufloxacin
• CAS NO: 108138-46-1
• Molecular Formula: C19H15F3N4O3
• Molecular Weight: 404.34
• Product Categories: Active Pharmaceutical Ingredients;Tosufloxacin
• Mol File: 108138-46-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 614.4°Cat760mmHg
• Flash Point: 325.4°C
• Appearance: /
• Density: 1.558g/cm³
• Vapor Pressure: 5.96E-16mmHg at 25°C
• CAS DataBase Reference: Tosufloxacin(CAS DataBase Reference)
• NIST Chemistry Reference: Tosufloxacin(108138-46-1)
• EPA Substance Registry System: Tosufloxacin(108138-46-1)

Safety Data

• Hazardous Substances Data: 108138-46-1(Hazardous Substances Data)

Usage

Pharmaceutical Applications

It is active against a wide range of Gram-positive and Gram-negative bacteria, including Acinetobacter spp., L. pneumophila and Campylobacter spp. Unlike many quinolones it is moderately active against L. monocytogenes. C. trachomatis is also moderately susceptible. It is active against some anaerobes, including the B. fragilis group. Activity against Mycobacterium spp. is limited. It is well absorbed by the oral route, achieving a plasma concentration of c. 1 mg/L 4 h after a 300 mg dose. Around 30–35% of the dose is eliminated in the urine, with an apparent elimination half-life of 6–7 h.Clinical experience is limited, but high clinical and bacteriological cure rates have been obtained in patients with skin and soft-tissue infections.

InChI:InChI=1/C19H15F3N4O3.C7H8O3S/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;1-6-2-4-7(5-3-6)11(8,9)10/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);2-5H,1H3,(H,8,9,10)

Related news

Antibacterial activity of Tosufloxacin (cas 108138-46-1) against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago08/27/2019

The minimum inhibitory concentrations (MICs) of tosufloxacin and other fluoroquinolone antimicrobials for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella (Branhamella) catarrhalis, isolated, between January 2003 and July 2004, from patients suspected of having respiratory or otor...detailed

Pharmacodynamic evaluation of Tosufloxacin (cas 108138-46-1) against Streptococcus pneumoniae in an in vitro model simulating serum concentration08/26/2019

We compared the antibacterial effects and the emergence of resistance to tosufloxacin or levofloxacin for Streptococcus pneumoniae by simulating the serum concentration according to the Japanese clinical regimens using an in vitro pharmacokinetic-pharmacodynamic model. For quinolone-susceptible ...detailed

Determination of structural, spectral, electronic and biological properties of Tosufloxacin (cas 108138-46-1) boron complexes and investigation of substituent effect08/25/2019

Quantum chemical calculations are performed over some boron complexes with tosufloxacin. Boron complex with fluorine atoms are optimized at HF/6-31+G(d), B3LYP/6-31+G(d) and M062X/6-31+G(d) level and the best level is determined by comparison of experimental and calculated results. The other com...detailed

Analysis of the spectroscopic characteristics on the binding interaction between Tosufloxacin (cas 108138-46-1) and bovine lactoferrin08/24/2019

The interaction between tosufloxacin (TELX) and bovine lactoferrin (BLF) in aqueous solution was analyzed by fluorescence spectroscopy and absorbance spectra. The binding parameters and energy-transfer efficiency parameters were determined and the mechanism of interaction was discussed. The effe...detailed

Short CommunicationKilling kinetics of minocycline, doxycycline and Tosufloxacin (cas 108138-46-1) against macrolide-resistant Mycoplasma pneumoniae08/23/2019

Macrolide-resistant Mycoplasma pneumoniae (MRMP) has emerged and is increasing worldwide. In a 2011 outbreak of MRMP infections in Japan, symptoms failed to improve in many patients who initially received macrolides; the therapeutic agent was then changed to minocycline (MIN), doxycycline (DOX) ...detailed

Emergence of Haemophilus influenzae with low susceptibility to quinolones and persistence in Tosufloxacin (cas 108138-46-1) treatment08/22/2019

BackgroundThe use of non-β-lactam agents has increased in Japan due to the prevalence of β-lactam-resistant pathogens. This study aimed to clarify the recent trend of antimicrobial susceptibility and molecular epidemiological features in Haemophilus influenzae.detailed

Relevant articles and documents

Naphthyridine antianaerobic compounds

The naphthyridine compounds having the formula: wherein R1 is hydrogen or a carboxy protecting group have unexpected and superior antianaerobic activity.